Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · IEX Real-Time Price · USD
3.780
+0.020 (0.53%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Design Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Design Therapeutics stock have an average target of 5.00, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 32.28% from the current stock price of 3.78.
Analyst Consensus: Hold
* Price targets were last updated on Mar 20, 2024.
Analyst Ratings
The average analyst rating for DSGN stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +5.82% | Mar 20, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +32.28% | Mar 20, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $7 → $4 | Hold | Maintains | $7 → $4 | +5.82% | Nov 14, 2023 |
| Wedbush | Wedbush | Buy → Hold Downgrades $6 | Buy → Hold | Downgrades | $6 | +58.73% | Aug 15, 2023 |
| SVB Leerink | SVB Leerink | Buy → Hold Downgrades $6 | Buy → Hold | Downgrades | $6 | +58.73% | Aug 15, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.20
from -1.19
EPS Next Year
-1.39
from -1.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 215.0M | 331.6M |
| Avg | n/a | n/a | n/a | 69.6M | 110.8M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 376.2% |
| Avg | - | - | - | - | 59.1% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.02 | -1.28 | -0.83 | 0.37 | 1.69 |
| Avg | -1.20 | -1.39 | -1.23 | -0.49 | -0.30 |
| Low | -1.46 | -1.67 | -1.53 | -1.28 | -2.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.